isoquinolines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	isoquinolines	go back to main search page
Accession:	CHEBI:24922	browse the term
Definition:	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
Synonyms:	xref_mesh:	MESH:D007546

show annotations for term's descendants Sort by:
Rat (533) Mouse (533) Human (540) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (4) Green Monkey (0) Naked Mole-rat (0) All
Genes (533)

isoquinolines

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Isoquinolines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

dopamine receptor D1

multiple interactions
affects localization

Isoquinolines binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Isoquinolines affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Isoquinolines results in increased activity of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

hematopoietic prostaglandin D synthase

multiple interactions

Isoquinolines analog binds to and results in decreased activity of HPGDS protein; Water affects the reaction [Isoquinolines analog binds to and results in decreased activity of HPGDS protein]

NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

Isoquinolines analog binds to and results in decreased activity of NR3C1 protein

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

(+)-Tetrandrine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity
decreases expression

tetrandrine results in decreased activity of ABCB1A protein
tetrandrine results in decreased expression of ABCB1

PMID:17273824 PMID:19840446

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

actin alpha 2, smooth muscle

multiple interactions

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions

AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

increases expression

tetrandrine results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

increases phosphorylation
decreases phosphorylation

tetrandrine results in increased phosphorylation of AKT1 protein
tetrandrine results in decreased phosphorylation of AKT1 protein

PMID:30549224 PMID:31255635

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

autophagy related 12

increases expression

tetrandrine results in increased expression of ATG12 protein

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 5

increases expression
decreases expression

tetrandrine results in increased expression of ATG5 protein
tetrandrine results in decreased expression of ATG5 protein

PMID:25266202 PMID:26822499

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

decreases expression

tetrandrine results in decreased expression of ATG7 protein

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

BCL2-antagonist/killer 1

increases expression

tetrandrine results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

increases expression

tetrandrine results in increased expression of BAX protein

PMID:26822499 PMID:31255635

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects response to substance
increases expression
multiple interactions
decreases expression

BCL2 protein affects the susceptibility to tetrandrine
tetrandrine results in increased expression of BCL2 protein
CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]
tetrandrine results in decreased expression of BCL2 mRNA; tetrandrine results in decreased expression of BCL2 protein

PMID:18495333 PMID:26302866 PMID:26822499 PMID:31255635

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

tetrandrine results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

beclin 1

increases expression
multiple interactions
decreases expression

tetrandrine results in increased expression of BECN1 protein
[sodium arsenite co-treated with tetrandrine] results in increased expression of BECN1 protein
tetrandrine results in decreased expression of BECN1 protein

PMID:25266202 PMID:26822499 PMID:30123091

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

decreases expression

tetrandrine results in decreased expression of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 5

affects binding
decreases expression

tetrandrine binds to BIRC5 promoter
tetrandrine results in decreased expression of BIRC5 mRNA

PMID:17968851 PMID:18495333

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 12

increases cleavage

tetrandrine results in increased cleavage of CASP12 protein

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

increases expression
increases cleavage
multiple interactions

tetrandrine results in increased expression of CASP3 protein
tetrandrine results in increased cleavage of CASP3 protein
3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]; tetrandrine results in increased cleavage of and results in increased activity of CASP3 protein

PMID:25266202 PMID:26302866 PMID:26822499 PMID:31255635

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression
increases cleavage

tetrandrine results in increased cleavage of and results in increased activity of CASP8 protein
tetrandrine results in increased expression of CASP8 protein
tetrandrine results in increased cleavage of CASP8 protein

PMID:25266202 PMID:26822499 PMID:31255635

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage

tetrandrine results in increased cleavage of and results in increased activity of CASP9 protein
tetrandrine results in increased cleavage of CASP9 protein

PMID:25266202 PMID:26822499

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin A2

increases expression

tetrandrine results in increased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

increases expression

tetrandrine results in increased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions
decreases expression
affects expression

[sodium arsenite co-treated with tetrandrine] affects the expression of CCND1 protein; [sodium arsenite co-treated with tetrandrine] results in decreased expression of CCND1 protein
tetrandrine results in decreased expression of CCND1 protein
tetrandrine affects the expression of CCND1 protein

PMID:30123091 PMID:31255635

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cadherin 1

decreases expression

tetrandrine results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

decreases expression

tetrandrine results in decreased expression of CDH2 protein

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase inhibitor 1A

increases expression
affects expression
multiple interactions

tetrandrine results in increased expression of CDKN1A
tetrandrine affects the expression of CDKN1A protein
[sodium arsenite co-treated with tetrandrine] affects the expression of CDKN1A protein

PMID:19840446 PMID:30123091

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[sodium arsenite co-treated with tetrandrine] results in increased expression of CDKN1B protein
tetrandrine results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]

PMID:17201889 PMID:22001142

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

collagen type I alpha 1 chain

decreases expression

tetrandrine results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; [tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 protein]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases glutathionylation

CYP3A4 protein results in increased glutathionylation of tetrandrine

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases glutathionylation
increases response to substance
multiple interactions

CYP3A5 protein results in increased glutathionylation of tetrandrine
CYP3A5 protein results in increased susceptibility to tetrandrine
CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione]; CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]

PMID:21992520 PMID:26302866

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

DNA-damage inducible transcript 3

increases expression

tetrandrine results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor receptor

decreases phosphorylation

tetrandrine results in decreased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

endonuclease G

decreases expression

tetrandrine results in decreased expression of ENDOG protein

NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases expression

[arsenite co-treated with tetrandrine] results in decreased expression of ERBB2 protein
tetrandrine results in decreased expression of ERBB2 protein

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

tetrandrine inhibits the reaction [Hexachlorocyclohexane results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box O3

multiple interactions

[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of FOXO3 protein; [sodium arsenite co-treated with tetrandrine] results in increased expression of FOXO3 protein; tetrandrine affects the expression of and affects the phosphorylation of FOXO3 protein

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P3

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]; resveratrol inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

growth factor receptor bound protein 2

decreases expression

tetrandrine results in decreased expression of GRB2 protein

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

glycogen synthase kinase 3 beta

decreases expression

tetrandrine results in decreased expression of GSK3B protein modified form

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

heat shock protein family A (Hsp70) member 5

increases expression

tetrandrine results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

multiple interactions
increases expression

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
tetrandrine results in increased expression of ICAM1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [[arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tetrandrine results in increased expression of ICAM1 protein]; [arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein; [arsenite co-treated with tetrandrine] results in increased expression of ICAM1 protein

PMID:17201889 PMID:31934280

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions
increases expression

[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions
decreases expression

resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]
tetrandrine results in decreased expression of IL17A mRNA

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]

PMID:22001142 PMID:26640276

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases phosphorylation

tetrandrine results in decreased phosphorylation of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lamin A/C

increases expression

tetrandrine results in increased expression of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

microtubule-associated protein 1 light chain 3 beta

increases expression

tetrandrine results in increased expression of MAP1LC3B

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]
tetrandrine results in increased phosphorylation of MAPK1 protein
[arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK1 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK1 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]

PMID:22001142 PMID:31934280

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]
tetrandrine results in increased phosphorylation of MAPK3 protein
[arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK3 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK3 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]

PMID:22001142 PMID:31934280

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

tetrandrine results in increased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

matrix metallopeptidase 2

multiple interactions

tetrandrine results in decreased expression of and results in decreased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions
decreases expression

tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]
tetrandrine results in decreased expression of MMP9 protein

PMID:22001142 PMID:30549224

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

multiple interactions
decreases expression

[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine results in decreased expression of and results in decreased phosphorylation of MTOR protein
tetrandrine results in decreased expression of MTOR protein; tetrandrine results in decreased expression of MTOR protein modified form

PMID:25266202 PMID:26822499 PMID:30123091 PMID:31255635

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFKB inhibitor alpha

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]

PMID:17201889 PMID:22001142

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

increases cleavage

tetrandrine results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

protein kinase AMP-activated catalytic subunit alpha 1

affects phosphorylation
multiple interactions

tetrandrine affects the phosphorylation of PRKAA1 protein
[sodium arsenite co-treated with tetrandrine] affects the phosphorylation of PRKAA1 protein

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases phosphorylation

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]
tetrandrine results in decreased expression of and results in decreased activity of RELA protein
tetrandrine results in increased phosphorylation of RELA protein

PMID:17201889 PMID:30549224 PMID:31255635

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RAR-related orphan receptor C

multiple interactions
decreases expression

tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]
tetrandrine results in decreased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

ribosomal protein S6

decreases expression

tetrandrine results in decreased expression of RPS6 protein modified form

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

regulatory associated protein of MTOR, complex 1

decreases expression

tetrandrine results in decreased expression of RAPTOR protein

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

stratifin

increases expression

tetrandrine results in increased expression of SFN protein

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

snail family transcriptional repressor 1

decreases expression

tetrandrine results in decreased expression of SNAI1 protein

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

SOS Ras/Rac guanine nucleotide exchange factor 1

decreases expression

tetrandrine results in decreased expression of SOS1 protein

NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107

G

sequestosome 1

decreases expression

tetrandrine results in decreased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

transforming growth factor, beta 1

multiple interactions

tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]

PMID:17201889 PMID:26640276

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

unc-51 like autophagy activating kinase 1

increases phosphorylation
decreases expression

tetrandrine results in increased phosphorylation of ULK1 protein
tetrandrine results in decreased expression of ULK1 protein

PMID:25266202 PMID:26822499

NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966

(+-)-Carnegine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

monoamine oxidase A

decreases activity

carnegine results in decreased activity of MAOA protein

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

(-)-Salsoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

monoamine oxidase A

decreases activity

salsoline results in decreased activity of MAOA protein

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

(R)-salsolinol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

salsolinol results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases expression

salsolinol results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

salsolinol results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

salsolinol results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

decreases expression

salsolinol results in decreased expression of BDNF protein

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

caspase 3

increases activity
increases cleavage
multiple interactions

salsolinol results in increased activity of CASP3 protein
salsolinol results in increased cleavage of CASP3 protein
Memantine inhibits the reaction [salsolinol results in increased activity of CASP3 protein]

PMID:17996985 PMID:23261589

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cAMP responsive element binding protein 1

decreases phosphorylation

salsolinol results in decreased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

estrogen receptor 1

increases activity

salsolinol results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

glial cell derived neurotrophic factor

decreases expression

salsolinol results in decreased expression of GDNF protein

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glycogen synthase kinase 3 beta

decreases phosphorylation

salsolinol results in decreased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

monoamine oxidase A

decreases activity

salsolinol results in decreased activity of MAOA protein

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen-activated protein kinase 8

increases activity

salsolinol results in increased activity of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

(RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

synuclein alpha

increases expression
multiple interactions

1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA mRNA; 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Acetylcysteine inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; coenzyme Q10 inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Selegiline inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

(RS)-coclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:58,758,703...58,758,787

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

(RS)-norcoclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:58,758,703...58,758,787

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

(S)-coclaurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:58,758,703...58,758,787

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

1,2,3,4-tetrahydroisoquinoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

1,2,3,4-tetrahydroisoquinoline binds to and results in increased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

dopamine receptor D3

affects binding

1,2,3,4-tetrahydroisoquinoline analog binds to DRD3 protein

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

interleukin 6

decreases expression
decreases response to substance

1,2,3,4-tetrahydroisoquinoline results in decreased expression of IL6 mRNA
IL6 protein results in decreased susceptibility to 1,2,3,4-tetrahydroisoquinoline

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

monoamine oxidase B

decreases activity

1,2,3,4-tetrahydroisoquinoline analog results in decreased activity of MAOB protein; 1,2,3,4-tetrahydroisoquinoline results in decreased activity of MAOB protein

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

phospholipase A2 group 4A

decreases expression

1,2,3,4-tetrahydroisoquinoline results in decreased expression of PLA2G4A mRNA

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

1-(5-isoquinolinesulfonyl)-2-methylpiperazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor alpha 1A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1D

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

angiotensinogen

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

alkaline phosphatase, biomineralization associated

decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

aquaporin 4

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions
decreases expression

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Ouabain results in increased expression of ATP1B1 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

Cd69 molecule

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Silicon Dioxide results in increased expression of CD69 protein]

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

ciliary neurotrophic factor

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]

NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]

PMID:9013560 PMID:16081525

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

E1A binding protein p300

multiple interactions
increases expression

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with Doxorubicin] results in increased expression of EP300 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in increased expression of EP300 protein

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

fibroblast growth factor 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor receptor 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

fibronectin 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FN1 mRNA]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of FOS mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FOS mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lead results in increased expression of FOS mRNA]

PMID:1932749 PMID:7945571 PMID:10381381 PMID:10693946

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

growth differentiation factor 15

multiple interactions

[SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glutamic--pyruvic transaminase

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [allyl alcohol results in increased secretion of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heme oxygenase 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [coniferaldehyde results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine receptor H 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dimaprit results in increased expression of HRH2 mRNA]

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

intercellular adhesion molecule 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of JUN mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Paraquat results in increased expression of JUN mRNA]

PMID:7662713 PMID:7945571

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [5,8,11,14-Eicosatetraynoic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [ciprofibrate analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Clofibrate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [pirinixic acid results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Thapsigargin analog results in increased expression of JUNB mRNA]

PMID:1932749 PMID:8764118

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

mitogen activated protein kinase kinase 1

decreases phosphorylation
multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K1 protein
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions
decreases phosphorylation

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K2 protein

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

metallothionein 1

multiple interactions
decreases expression

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of MT1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Copper results in increased activity of MT1 promoter]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [zinc chloride results in increased expression of MT1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of MT1 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of MT1 mRNA

PMID:11551972 PMID:14576086 PMID:15142038

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

phospholipase A2 group 4A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

protein kinase C, alpha

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCA protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein]

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCD protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCD protein]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prostaglandin-endoperoxide synthase 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]

PMID:18305957 PMID:18938131 PMID:19063610

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

retinoic acid receptor, alpha

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

solute carrier family 30 member 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

signal transducer and activator of transcription 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

telomerase reverse transcriptase

decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TERT protein

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

transforming growth factor, beta 1

multiple interactions
decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tight junction protein 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

multiple interactions

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein; [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein; [TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]

PMID:14654170 PMID:22298391

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tonsoku-like, DNA repair protein

multiple interactions

[TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein

NCBI chr 7:108,345,704...108,360,792
Ensembl chr 7:108,346,047...108,360,750

G

vascular endothelial growth factor A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

dimethisoquin results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 7 member A3

increases expression

Praziquantel results in increased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Praziquantel results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

annexin A2

increases expression

Praziquantel results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

BTG anti-proliferation factor 2

increases expression

Praziquantel results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

cyclin-dependent kinase inhibitor 1A

increases expression

Praziquantel results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

carboxylesterase 2H

increases expression

Praziquantel results in increased expression of CES2 mRNA

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects metabolic processing

CYP1A2 protein affects the metabolism of Praziquantel

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

affects metabolic processing

CYP2C19 protein affects the metabolism of Praziquantel

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing

CYP3A4 protein affects the metabolism of Praziquantel

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

interleukin 5

increases expression

Praziquantel results in increased expression of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

O-6-methylguanine-DNA methyltransferase

increases expression

Praziquantel results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

solute carrier family 22 member 2

multiple interactions

Praziquantel inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

transporter 1, ATP binding cassette subfamily B member

increases expression

Praziquantel results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

transient receptor potential cation channel, subfamily M, member 8

increases activity
decreases response to substance
multiple interactions

Praziquantel results in increased activity of TRPM8 protein
TRPM8 gene mutant form results in decreased susceptibility to Praziquantel
Calcium deficiency inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; Menthol inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; N-(3-aminopropyl)-2-(((3-methylphenyl) methyl)oxy)-N-(2-thienylmethyl)benzamide hydrochloride salt inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; Praziquantel inhibits the reaction [Menthol results in increased activity of TRPM8 protein]

NCBI chr 9:88,897,039...88,990,167
Ensembl chr 9:88,903,880...88,988,552

G

vascular endothelial growth factor A

decreases expression
multiple interactions

Praziquantel results in decreased expression of VEGFA mRNA; Praziquantel results in decreased expression of VEGFA protein
[Resveratrol co-treated with Praziquantel] results in decreased expression of VEGFA mRNA; [Resveratrol co-treated with Praziquantel] results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

4-phenyl-1,2,3,4-tetrahydroisoquinoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

trace-amine-associated receptor 1

multiple interactions
increases activity

[4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

5-(2-methylpiperazine-1-sulfonyl)isoquinoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor alpha 1A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1D

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

angiotensinogen

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

alkaline phosphatase, biomineralization associated

decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

aquaporin 4

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

ATPase Na+/K+ transporting subunit beta 1

decreases expression
multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of ATP1B1 mRNA
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Ouabain results in increased expression of ATP1B1 mRNA]

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

Cd69 molecule

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Silicon Dioxide results in increased expression of CD69 protein]

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

ciliary neurotrophic factor

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]

NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]

PMID:9013560 PMID:16081525

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

E1A binding protein p300

multiple interactions
increases expression

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with Doxorubicin] results in increased expression of EP300 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in increased expression of EP300 protein

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

fibroblast growth factor 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor receptor 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

fibronectin 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FN1 mRNA]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FOS mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lead results in increased expression of FOS mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of FOS mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]

PMID:1932749 PMID:7945571 PMID:10381381 PMID:10693946

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

growth differentiation factor 15

multiple interactions

[SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glutamic--pyruvic transaminase

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [allyl alcohol results in increased secretion of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heme oxygenase 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [coniferaldehyde results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine receptor H 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dimaprit results in increased expression of HRH2 mRNA]

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

intercellular adhesion molecule 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of JUN mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Paraquat results in increased expression of JUN mRNA]

PMID:7662713 PMID:7945571

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [5,8,11,14-Eicosatetraynoic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [ciprofibrate analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Clofibrate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [pirinixic acid results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Thapsigargin analog results in increased expression of JUNB mRNA]

PMID:1932749 PMID:8764118

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

mitogen activated protein kinase kinase 1

multiple interactions
decreases phosphorylation

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions
decreases phosphorylation

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K2 protein

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

metallothionein 1

decreases expression
multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of MT1 mRNA
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of MT1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Copper results in increased activity of MT1 promoter]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [zinc chloride results in increased expression of MT1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of MT1 mRNA]

PMID:11551972 PMID:14576086 PMID:15142038

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

phospholipase A2 group 4A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

protein kinase C, alpha

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCA protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein]

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCD protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCD protein]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prostaglandin-endoperoxide synthase 2

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]

PMID:18305957 PMID:18938131 PMID:19063610

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

retinoic acid receptor, alpha

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

solute carrier family 30 member 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

signal transducer and activator of transcription 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

telomerase reverse transcriptase

decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TERT protein

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

transforming growth factor, beta 1

multiple interactions
decreases activity

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tight junction protein 1

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

multiple interactions

[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein; [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein; [TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]

PMID:14654170 PMID:22298391

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tonsoku-like, DNA repair protein

multiple interactions

[TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein

NCBI chr 7:108,345,704...108,360,792
Ensembl chr 7:108,346,047...108,360,750

G

vascular endothelial growth factor A

multiple interactions

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

b-Dihydrotetrabenazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 18 member A2

affects binding

SLC18A2 protein binds to dihydrotetrabenazine

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

Berbamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 1

decreases expression

berbamine results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

BH3 interacting domain death agonist

decreases expression

berbamine results in decreased expression of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 5

decreases expression
affects binding

berbamine results in decreased expression of BIRC5 mRNA; berbamine results in decreased expression of BIRC5 protein
berbamine binds to BIRC5 promoter

PMID:17531122 PMID:17968851 PMID:19960011

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

increases activity

berbamine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

decreases expression

berbamine results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

component of inhibitor of nuclear factor kappa B kinase complex

decreases expression

berbamine results in decreased expression of CHUK protein

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

NFKB inhibitor alpha

decreases phosphorylation

berbamine results in decreased phosphorylation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

affects localization

berbamine affects the localization of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

TNF alpha induced protein 3

increases expression

berbamine results in increased expression of TNFAIP3 protein

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

bicuculline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activity-regulated cytoskeleton-associated protein

multiple interactions

Bicuculline inhibits the reaction [Propofol results in decreased expression of ARC protein]

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

caspase 3

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cAMP responsive element binding protein 1

increases phosphorylation

Bicuculline results in increased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased phosphorylation of ERN1 protein

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions
decreases expression

Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]
Bicuculline results in decreased expression of GABRA1 mRNA

PMID:1977069 PMID:9600394 PMID:27720918 PMID:29038840

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha6

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:27720918 PMID:29038840

NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769

G

gamma-aminobutyric acid type A receptor subunit beta1

multiple interactions

Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]
Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]

PMID:1977069 PMID:29038840

NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]

PMID:27720918 PMID:29038840

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit beta 3

decreases expression
multiple interactions

Bicuculline results in decreased expression of GABRB3 mRNA
Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:9600394 PMID:29038840

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961

G

gamma-aminobutyric acid type A receptor subunit gamma 1

decreases expression

Bicuculline results in decreased expression of GABRG1 mRNA

NCBI chr14:37,396,217...37,469,606
Ensembl chr14:37,396,294...37,635,956

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]]
Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]

PMID:27720918 PMID:29038840

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

gonadotropin releasing hormone 1

multiple interactions

Bicuculline affects the reaction [bisphenol A affects the secretion of GNRH1 protein]; Bicuculline promotes the reaction [manganese chloride results in increased secretion of GNRH1 protein]

PMID:18603625 PMID:26950200

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

glutamic--pyruvic transaminase

multiple interactions

Bicuculline promotes the reaction [Ethanol results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions
decreases expression

Bicuculline results in decreased expression of and results in decreased localization of GRIA1 protein
Bicuculline decreases expression of Gria1 protein in nucleus accumbens cultured cells
Bicuculline decreases expression of Gria1 protein on nucleus accumbens medium spiny neurons

CTD
RGD

PMID:19674091 PMID:19674091 PMID:24712995

RGD:4107725, RGD:405650624

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions
decreases expression

Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; Bicuculline results in decreased expression of and results in decreased localization of GRIA2 protein; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline decreases expression of Gria2 protein on nucleus accumbens medium spiny neurons
Bicuculline decreases expression of Gria2 protein in nucleus accumbens cultured cells
Bicuculline results in decreased expression of GRIA2 mRNA; Bicuculline results in decreased expression of GRIA2 protein

CTD
RGD

PMID:19674091 PMID:22262897 PMID:24712995 PMID:19674091

RGD:405650624, RGD:4107725

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein

NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793

G

histone deacetylase 5

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased expression of MAP3K5 protein

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

multiple interactions

Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK1 protein]
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]

PMID:19344668 PMID:19911010

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK3 protein]
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]

PMID:19344668 PMID:19911010

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[Bicuculline co-treated with Ethanol] results in increased expression of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

methyl CpG binding protein 2

multiple interactions
increases phosphorylation
increases expression

MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein]
Bicuculline results in increased phosphorylation of MECP2 protein
Bicuculline results in increased expression of MECP2 mRNA

NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689

G

multiple PDZ domain crumbs cell polarity complex component

affects response to substance

MPDZ protein affects the susceptibility to Bicuculline

NCBI chr 5:95,766,112...95,920,531
Ensembl chr 5:95,766,118...95,920,499

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

nerve growth factor

multiple interactions

Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

oxytocin receptor

multiple interactions

Bicuculline inhibits the reaction [oxytocin, Thr(4)-Gly(7)- results in increased activity of OXTR protein]

NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674

G

retinoic acid receptor, alpha

multiple interactions

[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

ryanodine receptor 1

increases response to substance

RYR1 results in increased susceptibility to Bicuculline

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

ryanodine receptor 2

increases response to substance

RYR2 results in increased susceptibility to Bicuculline

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

tyrosine hydroxylase

multiple interactions

Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

cephaeline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

decreases expression

cephaelin results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

decreases expression

cephaelin results in decreased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

decreases expression

cephaelin results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

interleukin 6 receptor

decreases expression

cephaelin results in decreased expression of IL6R protein modified form

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

vascular endothelial growth factor A

decreases expression

cephaelin results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

cepharanthine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

cepharanthine results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

potassium voltage-gated channel subfamily H member 2

decreases activity

cepharanthine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

cepharanthine results in increased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

mechanistic target of rapamycin kinase

decreases expression

cepharanthine results in decreased expression of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

poly (ADP-ribose) polymerase 1

decreases expression

cepharanthine results in decreased expression of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

tumor protein p53

increases expression

cepharanthine results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

corydaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

Corydaline inhibits the reaction [Morphine increases expression of Gria1 protein in the striatum]

RGD

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

corynoline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamic--pyruvic transaminase

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]]; corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 beta

increases phosphorylation

corynoline results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

heme oxygenase 1

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]

PMID:34477289 PMID:36161741

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 beta

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]

PMID:34477289 PMID:36161741

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

myeloperoxidase

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of MPO protein]; corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]

PMID:34477289 PMID:36161741

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFE2L2 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]

PMID:34477289 PMID:36161741

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]

PMID:34477289 PMID:36161741

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]

PMID:34477289 PMID:36161741

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

sirtuin 1

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]]; corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

tumor necrosis factor

multiple interactions

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]

PMID:34477289 PMID:36161741

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

dauricine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases glutathionylation
multiple interactions

CYP3A4 protein results in increased glutathionylation of dauricine
[CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of N-desmethyldauricine; [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of quinone methide; CYP3A4 protein results in increased oxidation of and results in increased activity of dauricine; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

debrisoquin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
increases metabolic processing
increases hydroxylation
affects metabolic processing
increases abundance
decreases metabolic processing
decreases response to substance

CYP2D6 gene mutant form affects the metabolism of and affects the hydroxylation of Debrisoquin; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Debrisoquin]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of Debrisoquin metabolite]
CYP2D6 protein results in increased metabolism of Debrisoquin
CYP2D6 protein results in increased hydroxylation of Debrisoquin
CYP2D6 protein affects the metabolism of Debrisoquin; CYP2D6 protein polymorphism affects the metabolism of Debrisoquin
CYP2D6 gene mutant form results in decreased metabolism of Debrisoquin; CYP2D6 gene polymorphism results in decreased metabolism of Debrisoquin

PMID:3577206 PMID:6603386 PMID:8946814 PMID:11673748 PMID:11823760 More...

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

drotaverine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

drotaverin results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

emetine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

argonaute RISC catalytic component 3

multiple interactions

Emetine inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA]

NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230

G

A-kinase anchoring protein 9

multiple interactions

Emetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein]

NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606

G

androgen receptor

multiple interactions

Emetine binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BRCA1, DNA repair associated

multiple interactions

Emetine inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA]

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

cell cycle associated protein 1

multiple interactions

Emetine inhibits the reaction [sodium arsenite affects the localization of CAPRIN1 protein]

NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502

G

caspase 3

increases activity

Emetine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Emetine results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cell division cycle and apoptosis regulator 1

multiple interactions

Emetine inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

C-C motif chemokine ligand 2

decreases expression

Emetine results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

decreases expression

Emetine results in decreased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression

Emetine results in decreased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

decreases expression

Emetine results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cAMP responsive element binding protein 1

multiple interactions

Emetine inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

estrogen receptor 1

multiple interactions

Emetine binds to and results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

Emetine binds to and results in decreased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

insulin-like growth factor 2 mRNA binding protein 1

multiple interactions

IGF2BP1 protein affects the reaction [Emetine results in increased degradation of MYCN protein]

NCBI chr10:80,908,300...80,951,097
Ensembl chr10:80,908,076...80,951,129

G

interleukin 6 receptor

decreases expression

Emetine results in decreased expression of IL6R protein modified form

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation
increases phosphorylation

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein]
MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]

PMID:15772366 PMID:26332055

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein]

PMID:16364386 PMID:26332055

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

increases phosphorylation
decreases phosphorylation
multiple interactions

Emetine results in increased phosphorylation of MAPK3 protein
Emetine results in decreased phosphorylation of MAPK3 protein
MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein]

PMID:15772366 PMID:26332055

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

decreases expression

Emetine results in decreased expression of MAPT protein

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

matrix metallopeptidase 2

decreases activity
multiple interactions
decreases expression

Emetine results in decreased activity of MMP2 protein
MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]
Emetine results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

decreases activity
multiple interactions
decreases expression

Emetine results in decreased activity of MMP9 protein
MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]
Emetine results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
increases degradation

IGF2BP1 protein affects the reaction [Emetine results in increased degradation of MYCN protein]

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

neurofilament heavy chain

decreases degradation

Emetine results in decreased degradation of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

G

neurofilament light chain

decreases degradation

Emetine results in decreased degradation of NEFL mRNA

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

decreases degradation

Emetine results in decreased degradation of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Emetine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

poly (ADP-ribose) polymerase 1

increases cleavage

Emetine results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

progesterone receptor

multiple interactions

Emetine binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

reversion-inducing-cysteine-rich protein with kazal motifs

decreases expression

Emetine results in decreased expression of RECK mRNA

NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502

G

RPTOR independent companion of MTOR, complex 2

multiple interactions

Emetine inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA]

NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426

G

TAR DNA binding protein

multiple interactions

Emetine affects the reaction [TARDBP protein binds to TIA1 protein]; Emetine affects the reaction [TARDBP protein binds to TIAL1 protein]

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

transforming growth factor, beta 1

decreases activity

Emetine results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

thyroid hormone receptor alpha

multiple interactions

Emetine binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

Emetine binds to and results in decreased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

TIA1 cytotoxic granule-associated RNA binding protein

multiple interactions

Emetine affects the reaction [TARDBP protein binds to TIA1 protein]

NCBI chr 4:118,852,765...118,883,252
Ensembl chr 4:118,852,837...118,880,586

G

Tia1 cytotoxic granule-associated RNA binding protein-like 1

multiple interactions

Emetine affects the reaction [TARDBP protein binds to TIAL1 protein]

NCBI chr 1:183,008,358...183,045,092
Ensembl chr 1:183,009,253...183,031,637

G

vascular endothelial growth factor A

decreases expression

Emetine results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-linked inhibitor of apoptosis

multiple interactions

Emetine inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA]

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

fasudil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

decreases expression

fasudil results in decreased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

AKT serine/threonine kinase 1

multiple interactions

fasudil results in increased phosphorylation of and results in increased activity of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arginase 1

increases expression

fasudil results in increased expression of ARG1 protein

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho guanine nucleotide exchange factor 11

decreases expression

fasudil results in decreased expression of ARHGEF11 mRNA; fasudil results in decreased expression of ARHGEF11 protein

NCBI chr 2:173,074,383...173,195,962
Ensembl chr 2:173,074,368...173,196,010

G

BCL2 associated X, apoptosis regulator

multiple interactions

fasudil inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; fasudil inhibits the reaction [Streptozocin results in increased expression of BAX protein]

PMID:22429817 PMID:30088170

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
increases expression

fasudil inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]
fasudil results in increased expression of BCL2 protein

PMID:17761835 PMID:22429817 PMID:30088170

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone gamma-carboxyglutamate protein

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

caspase 3

multiple interactions

fasudil inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA]

PMID:17761835 PMID:30088170

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

fasudil inhibits the reaction [Acetaminophen results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

fasudil affects the reaction [Daunorubicin affects the expression of CDKN1B mRNA]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cofilin 1

decreases expression
multiple interactions

fasudil results in decreased expression of CFL1 mRNA
fasudil inhibits the reaction [Streptozocin results in increased phosphorylation of CFL1 protein]
fasudil results in decreased expression of and results in decreased phosphorylation of CFL1 protein

PMID:22062134 PMID:26172442

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

fasudil results in decreased expression of COL1A1 mRNA
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA

PMID:22465603 PMID:31935364

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression

fasudil results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

fibronectin 1

multiple interactions

fasudil inhibits the reaction [Streptozocin results in increased expression of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

growth associated protein 43

multiple interactions

[fasudil co-treated with Methylmercury Compounds] results in increased expression of and results in increased phosphorylation of GAP43 protein

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

fasudil inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heme oxygenase 1

affects expression

fasudil affects the expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

multiple interactions

fasudil inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

increases expression

fasudil results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

multiple interactions

fasudil inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of IL1B protein]; fasudil inhibits the reaction [Paraquat results in increased expression of IL1B protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of IL1B protein]
fasudil inhibits the reaction [Acetaminophen results in increased expression of IL1B protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]

PMID:30088170 PMID:30462329 PMID:30924981 PMID:34078832

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of IL6 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of IL6 protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of IL6 protein]
fasudil inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]

PMID:30088170 PMID:30462329 PMID:30924981 PMID:34078832

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

LIM domain kinase 2

multiple interactions

fasudil inhibits the reaction [Streptozocin results in increased phosphorylation of LIMK2 protein]

NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007

G

mitogen activated protein kinase kinase kinase 7

decreases expression

fasudil results in decreased expression of MAP3K7 protein

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

microtubule-associated protein tau

multiple interactions

fasudil inhibits the reaction [methylmercuric chloride results in decreased expression of MAPT protein]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

matrix metallopeptidase 8

affects expression

fasudil affects the expression of MMP8 mRNA

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

matrix metallopeptidase 9

affects expression

fasudil affects the expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

myosin heavy chain 7

decreases expression

fasudil results in decreased expression of MYH7 mRNA

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin, light chain 1

multiple interactions

fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]

NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261

G

NFKB inhibitor alpha

multiple interactions

fasudil inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of NFKBIA protein]

PMID:23376009 PMID:30924981

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPHS1 adhesion molecule, nephrin

multiple interactions

fasudil inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 protein]

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

natriuretic peptide A

decreases expression

fasudil results in decreased expression of NPPA mRNA

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

decreases expression

fasudil results in decreased expression of NPPB mRNA

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

protein kinase N2

decreases activity

fasudil results in decreased activity of PKN2 protein

NCBI chr 2:231,793,584...231,898,953
Ensembl chr 2:231,793,584...231,898,953

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Paraquat results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of PPP1R12A protein modified form]

PMID:22429817 PMID:30088170 PMID:37963515

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

fasudil inhibits the reaction [Methylmercury Compounds results in increased phosphorylation of RELA protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of and affects the localization of RELA protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein]

PMID:23376009 PMID:30462329 PMID:30924981

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

rhodopsin

multiple interactions

fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO protein]
fasudil inhibits the reaction [Paraquat results in increased expression of RHO protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO protein]; fasudil inhibits the reaction [Paraquat results in increased expression of RHO protein]

PMID:30088170 PMID:30924981

NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773

G

ras homolog family member A

decreases expression
multiple interactions

fasudil results in decreased expression of RHOA mRNA; fasudil results in decreased expression of RHOA protein
fasudil inhibits the reaction [Acetaminophen results in increased expression of RHOA protein]

PMID:26172442 PMID:34078832

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

Rho-associated coiled-coil containing protein kinase 1

decreases expression
multiple interactions

fasudil results in decreased expression of ROCK1 mRNA; fasudil results in decreased expression of ROCK1 protein
fasudil inhibits the reaction [Acetaminophen results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of ROCK1 protein]
fasudil affects the reaction [Daunorubicin affects the expression of ROCK1 mRNA]; fasudil inhibits the reaction [Paraquat results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [Streptozocin results in increased activity of ROCK1 protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of ROCK1 mRNA]

PMID:20037814 PMID:22429817 PMID:23376009 PMID:26172442 PMID:30088170 More...

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

Rho-associated coiled-coil containing protein kinase 2

decreases activity
multiple interactions

fasudil results in decreased activity of ROCK2 protein
fasudil inhibits the reaction [Acetaminophen results in increased expression of ROCK2 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK2 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK2 protein]

PMID:10998351 PMID:30924981 PMID:34078832

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

ribosomal protein S6 kinase A1

decreases activity

fasudil results in decreased activity of RPS6KA1 protein

NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272

G

ribosomal protein S6 kinase A5

decreases activity

fasudil results in decreased activity of RPS6KA5 protein

NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224

G

ribosomal protein S6 kinase B1

decreases activity

fasudil results in decreased activity of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

RUNX family transcription factor 2

multiple interactions

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

solute carrier family 12 member 2

increases expression

fasudil results in increased expression of SLC12A2 protein

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

synuclein alpha

multiple interactions

fasudil inhibits the reaction [propionic acid results in increased expression of SNCA mRNA]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

synaptophysin

multiple interactions

fasudil inhibits the reaction [Rotenone results in decreased expression of SYP mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of SYP mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of SYP protein]

PMID:22062134 PMID:32481507

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

transforming growth factor, beta 1

decreases expression
multiple interactions

fasudil results in decreased expression of TGFB1 protein
fasudil inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]

PMID:22465603 PMID:23376009

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

multiple interactions

[[propionic acid co-treated with fasudil] affects the susceptibility to Rotenone] which results in increased expression of TH mRNA

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

TIMP metallopeptidase inhibitor 1

affects expression

fasudil affects the expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tight junction protein 1

multiple interactions

fasudil inhibits the reaction [Paraquat results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

affects expression
multiple interactions

fasudil affects the expression of TNF mRNA
fasudil inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of TNF protein]
fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of TNF protein]; fasudil inhibits the reaction [Paraquat results in increased expression of TNF protein]

PMID:26120273 PMID:30088170 PMID:30462329 PMID:30924981 PMID:34078832

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily C, member 1

multiple interactions

fasudil inhibits the reaction [Oxygen deficiency results in increased expression of TRPC1 protein]

NCBI chr 8:96,263,322...96,314,220
Ensembl chr 8:96,263,329...96,314,276

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions

fasudil inhibits the reaction [Oxygen deficiency results in increased expression of TRPC6 protein]

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

vascular endothelial growth factor A

affects expression

fasudil affects the expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Hydrastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group I, member 2

increases activity

hydrastine results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

Isoliensinine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

isoliensinine results in decreased phosphorylation of AKT1 protein
isoliensinine promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2, apoptosis regulator

decreases expression
multiple interactions
affects expression

isoliensinine results in decreased expression of BCL2 mRNA; isoliensinine results in decreased expression of BCL2 protein
isoliensinine inhibits the reaction [RELA protein binds to BCL2 promoter]
isoliensinine affects the expression of BCL2 protein

PMID:26219228 PMID:26389520

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

isoliensinine inhibits the reaction [RELA protein binds to BCL2L1 promoter]
isoliensinine results in decreased expression of BCL2L1 mRNA; isoliensinine results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 3

increases activity
multiple interactions
increases cleavage

isoliensinine results in increased activity of CASP3 protein
Acetylcysteine inhibits the reaction [isoliensinine results in increased cleavage of CASP3 protein]; RELA protein mutant form inhibits the reaction [isoliensinine results in increased activity of CASP3 protein]

PMID:26219228 PMID:26389520

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases cleavage

isoliensinine results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin E1

decreases expression

isoliensinine results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin-dependent kinase inhibitor 1A

increases expression

isoliensinine results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

isoliensinine results in increased phosphorylation of MAPK8 protein
Acetylcysteine inhibits the reaction [isoliensinine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

matrix metallopeptidase 9

decreases expression

isoliensinine results in decreased expression of MMP9 mRNA; isoliensinine results in decreased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

isoliensinine results in increased cleavage of PARP1 protein
Acetylcysteine inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

RELA proto-oncogene, NF-kB subunit

decreases phosphorylation
multiple interactions

isoliensinine results in decreased phosphorylation of RELA protein
isoliensinine inhibits the reaction [RELA protein binds to BCL2 promoter]; isoliensinine inhibits the reaction [RELA protein binds to BCL2L1 promoter]; RELA protein mutant form inhibits the reaction [isoliensinine results in increased activity of CASP3 protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

isoquinoline-1,5-diol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

multiple interactions

[1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

endothelin 1

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

endothelin receptor type B

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

high mobility group box 1

multiple interactions

1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases expression
decreases activity

1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein]
1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]
1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein

PMID:12824290 PMID:19833176 PMID:25517228

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

sirtuin 1

multiple interactions

1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

Liensinine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

liensinine results in decreased expression of and results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

caspase 1

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin dependent kinase 2

affects binding
decreases expression

liensinine binds to CDK2 protein
liensinine results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

affects binding
decreases expression

liensinine binds to CDK4 protein
liensinine results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cathepsin B

increases expression

liensinine results in increased expression of CTSB protein

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

increases expression

liensinine results in increased expression of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

increases expression

liensinine results in increased expression of CTSL protein

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases chemical synthesis

CYP3A4 protein results in increased chemical synthesis of liensinine

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

H2A.X variant histone

increases phosphorylation

liensinine results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

heme oxygenase 1

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in decreased expression of HMOX1 protein]
liensinine promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 10

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Kelch-like ECH-associated protein 1

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

mitogen activated protein kinase 1

multiple interactions

2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [liensinine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; liensinine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [liensinine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; liensinine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

NFE2 like bZIP transcription factor 2

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides affects the localization of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

tumor necrosis factor

multiple interactions

liensinine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

uncoupling protein 1

increases expression

liensinine results in increased expression of UCP1 protein

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

Mivacurium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

butyrylcholinesterase

affects response to substance
increases response to substance

BCHE affects the susceptibility to mivacurium; BCHE gene polymorphism affects the susceptibility to mivacurium; BCHE protein affects the susceptibility to mivacurium
BCHE gene mutant form results in increased susceptibility to mivacurium

PMID:9024049 PMID:15688329 PMID:16788378 PMID:16884476 PMID:18399847 More...

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

mivacurium inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 2

multiple interactions

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of BIRC2 protein]

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

caspase 8

multiple interactions

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide affects the localization of and results in increased cleavage of and results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

casein kinase 1, alpha 1

decreases activity

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide results in decreased activity of CSNK1A1 protein

NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271

G

T-box transcription factor 3

decreases expression

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide results in decreased expression of TBX3 mRNA

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

TNF receptor superfamily member 10b

increases expression

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide results in increased expression of TNFRSF10A protein

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

TNF superfamily member 10

multiple interactions

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of BIRC2 protein]; N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of XIAP protein]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

X-linked inhibitor of apoptosis

multiple interactions

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of XIAP protein]

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [aranidipine results in increased expression of ABCA1 protein]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of ABCB1 protein

PMID:12926078 PMID:23466342

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA]

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]

PMID:26049102 PMID:27743861 PMID:31300867

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

adenylate cyclase activating polypeptide 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADCYAP1 protein results in increased expression of SELENOT mRNA]

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

adrenomedullin

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADM protein results in decreased activity of MAPK1 protein]

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A2B receptor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADORA2B protein inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]]

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

aryl hydrocarbon receptor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AT-hook transcription factor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in decreased expression of AKNA mRNA]

NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017

G

AKT serine/threonine kinase 1

multiple interactions
decreases activity
affects phosphorylation

SB 203580 inhibits the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the phosphorylation of AKT1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of AKT1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of AKT1 protein

PMID:10998351 PMID:17640974 PMID:39233265

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apolipoprotein A1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of CETP mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of CETP protein]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein E

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

aquaporin 3 (Gill blood group)

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [VIP protein results in increased expression of AQP3 mRNA]

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

amphiregulin

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein]

PMID:15967414 PMID:16888076

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

activating transcription factor 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]

PMID:12164941 PMID:16671086 PMID:22188298

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

activating transcription factor 3

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of ATF3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of ATF3 protein]

PMID:25136830 PMID:30409902

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

BCL2-associated agonist of cell death

multiple interactions
decreases activity

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of and results in decreased phosphorylation of BAD protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [BAD protein binds to BCL2L1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

Bcl2-like 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [BAD protein binds to BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

baculoviral IAP repeat-containing 5

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in decreased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 4

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of BMP4 mRNA]

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

calcium/calmodulin dependent serine protein kinase

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein]

NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694

G

caspase 3

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]

PMID:21873648 PMID:32115946

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CCL2]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of CCND1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]

PMID:17680988 PMID:22493441 PMID:26964897

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

Cd68 molecule

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CD86 molecule

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]]

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN2B mRNA]

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

CCAAT/enhancer binding protein alpha

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPB mRNA]

PMID:14684744 PMID:21220312

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CF transmembrane conductance regulator

multiple interactions
decreases activity
affects localization

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Octanol results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of CFTR protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of CFTR protein

PMID:12606488 PMID:14744818 PMID:14967738 PMID:15763242 PMID:15994425 More...

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

glycoprotein hormones, alpha polypeptide

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF2 protein]

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

chitinase 3-like 3

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA]

NCBI chr 2:193,808,135...193,825,511
Ensembl chr 2:193,812,431...193,825,513

G

collagen type I alpha 1 chain

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

carnitine palmitoyltransferase 1A

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased expression of CPT1A mRNA]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of CREB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(3-3,4-p-menthadien-(1,8)-yl)olivetol results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [alternariol results in increased expression of CREB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [O-1602 compound results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of CREB1 mRNA]

PMID:10908723 PMID:12164941 PMID:15385614 PMID:15522277 PMID:16159392 More...

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sodium Oxybate results in increased phosphorylation of CREBBP protein]

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

CREB regulated transcription coactivator 2

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]

NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763

G

catenin beta 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]

PMID:22493441 PMID:26964897

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [3',4'-dimethoxyflavone results in increased expression of CYP11B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA]

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP19A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Water Pollutants, Chemical analog results in increased expression of CYP19A1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein]

PMID:19147701 PMID:20096755 PMID:20678559 PMID:21932247 PMID:28571770

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TNF protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]

PMID:20093341 PMID:25233930

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

iodothyronine deiodinase 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithocholic Acid results in increased activity of DIO2 protein]

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

dopamine receptor D1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

endothelin 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]

PMID:14759557 PMID:15245872

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin 3

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]

NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093

G

endothelin receptor type B

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

epidermal growth factor receptor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of EGFR mRNA]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of EGR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 protein]

PMID:15621046 PMID:22174042

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

epiregulin

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA]

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endogenous retrovirus group FRD member 1, envelope

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

coagulation factor II, thrombin

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein]

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

Fas cell surface death receptor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dieldrin results in increased expression of FOS mRNA]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOS mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

PMID:10864209 PMID:15179140 PMID:21177286 PMID:31068361

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA]

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL2 mRNA]

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

follicle stimulating hormone subunit beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Estradiol]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased secretion of Progesterone]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased phosphorylation of TSC2 protein]

PMID:15967414 PMID:17510244 PMID:18535249 PMID:21177760

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gastrin

decreases secretion

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of GAST protein

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

glucagon

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glial cells missing transcription factor 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein]

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

growth hormone 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in decreased expression of GH1 mRNA]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

G protein-coupled estrogen receptor 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]

PMID:22645130 PMID:37372083

NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889

G

glutamic--pyruvic transaminase

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in decreased expression of and results in decreased activity of GPX1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [roflupram inhibits the reaction [Copper Sulfate results in decreased expression of GPX1 protein]]

PMID:24910983 PMID:37353053

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein]

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

gasdermin D

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD protein]

NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055

G

glycogen synthase kinase 3 beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Caffeine results in increased phosphorylation of GSK3B protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [oxyphylla A results in increased phosphorylation of GSK3B protein]

PMID:21229324 PMID:39233265

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

hyaluronan synthase 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA]

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

heme oxygenase 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of HMOX1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [hexacyanoferrate III results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]

PMID:15179140 PMID:16439612 PMID:19483313

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of HSD11B1 mRNA]

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

inhibitor of DNA binding 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Iloprost results in increased expression of ID1 mRNA]

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

immunoglobulin heavy constant epsilon

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IKBKB mRNA]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 18

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Histamine results in increased expression of IL18 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL18 protein]

PMID:16723495 PMID:37353053

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of IL1B protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL1B protein]

PMID:23284918 PMID:29079362 PMID:37353053

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

multiple interactions
decreases secretion
decreases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL4 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL4 mRNA

PMID:11886533 PMID:12230500

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

decreases expression
decreases secretion

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL5 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of PLIN2 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PLIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARGC1A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of UCP1 protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

insulin receptor substrate 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IRS1 mRNA]

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

integrin subunit alpha M

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

PMID:15179140 PMID:18755854 PMID:21177286

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

JunD proto-oncogene, AP-1 transcription factor subunit

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

potassium voltage-gated channel subfamily E regulatory subunit 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]]

NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNH2 protein]

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 2

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNJ2 protein]

NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445

G

potassium voltage-gated channel subfamily Q member 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]]

NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669

G

kininogen 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [KNG1 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]]

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

leptin

multiple interactions
decreases response to substance

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CCL2]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased susceptibility to LEP protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]

PMID:11342529 PMID:19254925 PMID:28571770

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PGR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of TNFAIP6 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased secretion of Progesterone]

PMID:15967414 PMID:21220312

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipase E, hormone sensitive type

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Thioctic Acid results in increased phosphorylation of LIPE protein]

PMID:22941773 PMID:23362264 PMID:29288687

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADM protein results in decreased activity of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK1 protein

PMID:10374718 PMID:11675405 PMID:12657697 PMID:16099847 PMID:16439612 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Ro 31-8425 inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ro 31-8425 promotes the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]]

PMID:11675405 PMID:12657697 PMID:15385614 PMID:16099847 PMID:16439612 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

melanocyte inducing transcription factor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [isosakuranetin results in increased expression of MITF protein]

NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145

G

MLX interacting protein-like

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]]

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

matrix metallopeptidase 9

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of MMP9 mRNA]

PMID:24929186 PMID:29079362

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mannose receptor, C type 1

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein]

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin heavy chain 4

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 protein]

NCBI chr10:51,923,149...51,946,297
Ensembl chr10:51,885,913...51,946,295

G

myosin heavy chain 7

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Phenylephrine results in increased expression of MYH7 mRNA]

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myogenin

multiple interactions

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG protein]

NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039

G

NFE2 like bZIP transcription factor 2